[go: up one dir, main page]

AR001687A1 - Producto farmacéutico apropiado para el tratamiento parenteral de daños producidos por enfermedades isquemicas focales permanentes que comprende (s)-adenosil-l-metionina (SAMe) - Google Patents

Producto farmacéutico apropiado para el tratamiento parenteral de daños producidos por enfermedades isquemicas focales permanentes que comprende (s)-adenosil-l-metionina (SAMe)

Info

Publication number
AR001687A1
AR001687A1 AR33625596A AR33625596A AR001687A1 AR 001687 A1 AR001687 A1 AR 001687A1 AR 33625596 A AR33625596 A AR 33625596A AR 33625596 A AR33625596 A AR 33625596A AR 001687 A1 AR001687 A1 AR 001687A1
Authority
AR
Argentina
Prior art keywords
adenosyl
methionine
damage caused
pharmaceutical product
ischemic diseases
Prior art date
Application number
AR33625596A
Other languages
English (en)
Inventor
G Nemeth
Di C Padova
L Szabo
G Grof
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of AR001687A1 publication Critical patent/AR001687A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un producto farmacéutico apropiado para el tratamiento parenteral de danos producidos por enfermedades isquémicas focales permanentesque comprende una cantidad efectiva de (S)-adenosil-L-metionina y sus sales fisiológicamentetoleradas, para obtener una dosis de al menos2000 mg/día/paciente.
AR33625596A 1995-04-26 1996-04-23 Producto farmacéutico apropiado para el tratamiento parenteral de daños producidos por enfermedades isquemicas focales permanentes que comprende (s)-adenosil-l-metionina (SAMe) AR001687A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19515275A DE19515275A1 (de) 1995-04-26 1995-04-26 Neue Verwendung von (S)-Adenosyl-L-methionin(SAMe)

Publications (1)

Publication Number Publication Date
AR001687A1 true AR001687A1 (es) 1997-11-26

Family

ID=7760373

Family Applications (1)

Application Number Title Priority Date Filing Date
AR33625596A AR001687A1 (es) 1995-04-26 1996-04-23 Producto farmacéutico apropiado para el tratamiento parenteral de daños producidos por enfermedades isquemicas focales permanentes que comprende (s)-adenosil-l-metionina (SAMe)

Country Status (15)

Country Link
EP (1) EP0822820A1 (es)
JP (1) JPH11504023A (es)
KR (1) KR19990008061A (es)
CN (1) CN1182367A (es)
AR (1) AR001687A1 (es)
AU (1) AU5646396A (es)
CA (1) CA2216854A1 (es)
CZ (1) CZ330597A3 (es)
DE (1) DE19515275A1 (es)
HR (1) HRP960196A2 (es)
IL (1) IL117844A0 (es)
MX (1) MX9707735A (es)
NO (1) NO974941L (es)
WO (1) WO1996033727A1 (es)
ZA (1) ZA963296B (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE37913B1 (en) * 1972-08-02 1977-11-09 Bioresearch Sas Salt of s-adenosyl-l-methionine
JPS59139319A (ja) * 1983-01-31 1984-08-10 Fuji Kagaku Kogyo Kk 脳障害による身体機能障害治療剤
JPH02290896A (ja) * 1989-04-28 1990-11-30 Fuji Kagaku Kogyo Kk 新規なｓ―アデノシルメチオニン誘導体
DE4425280C2 (de) * 1994-07-16 1997-05-07 Knoll Ag Verwendung von (S)-Adenosyl-L-methionin und dessen physiologisch verträglichen Salzen zur Behandlung von Reperfusionsschäden, die nach temporärer fokaler Ischämie ausgelöst werden

Also Published As

Publication number Publication date
KR19990008061A (ko) 1999-01-25
JPH11504023A (ja) 1999-04-06
NO974941D0 (no) 1997-10-24
ZA963296B (en) 1997-10-27
WO1996033727A1 (de) 1996-10-31
CA2216854A1 (en) 1996-10-13
CN1182367A (zh) 1998-05-20
AU5646396A (en) 1996-11-18
HRP960196A2 (en) 1998-02-28
CZ330597A3 (cs) 1998-02-18
MX9707735A (es) 1997-12-31
IL117844A0 (en) 1996-08-04
EP0822820A1 (de) 1998-02-11
DE19515275A1 (de) 1996-10-31
NO974941L (no) 1997-10-24

Similar Documents

Publication Publication Date Title
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
AR033796A1 (es) Composicion farmaceutica
MX9701342A (es) Formulacion cosolvente de tirilazad para administracion parenteral.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
MX9307885A (es) Aplicacion de la carbamzaepina y oxcarbazepian para la obtencion de medicamentos para el tratamiento de la enfermedad de parkinson y los sindromes parkinsonianos.
GT200000183A (es) Aminoacidos biciclicos como agentes farmaceuticos.
DE69331409D1 (de) Oral 1alpha-hydroxyprevitamin d
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
MX9203444A (es) Medicamentos.
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
ES2077199T3 (es) Nuevas piperacinas 1,4-disustituidas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
ES2142432T3 (es) Forma de dosificacion de la gepirona.
BR9610480A (pt) Inibição do fator alfa de necrose tumoral
ATE173923T1 (de) Oralanzuwendende flüssige arzneizubereitung enthaltend 2-(4-isobutylphenyl)propionsäure
ES2524369T3 (es) Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento
KR970025615A (ko) 암 전이 억제제
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
FI934680A0 (fi) Arylmorfolin, framstaellning och anvaending
ES2151922T3 (es) Uso de aspirina para la fabricacion de un medicamento para mejorar la perfusion sanguinea en el utero.
AR006281A1 (es) Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares